Omnicell (NASDAQ:OMCL) Rating Increased to Equal Weight at Barclays

Barclays upgraded shares of Omnicell (NASDAQ:OMCL) from an underweight rating to an equal weight rating in a report issued on Friday morning, Marketbeat.com reports. They currently have $39.00 price objective on the stock, up from their previous price objective of $26.00.

OMCL has been the subject of several other reports. Benchmark reaffirmed a buy rating and issued a $38.00 target price on shares of Omnicell in a research report on Monday, July 15th. StockNews.com downgraded Omnicell from a buy rating to a hold rating in a research report on Tuesday, July 16th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Omnicell presently has an average rating of Hold and an average price target of $38.00.

Omnicell Stock Up 2.0 %

NASDAQ OMCL opened at $40.00 on Friday. Omnicell has a 52 week low of $25.12 and a 52 week high of $66.65. The company has a quick ratio of 2.13, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. The business’s fifty day simple moving average is $28.84 and its 200-day simple moving average is $29.04. The firm has a market cap of $1.84 billion, a PE ratio of -86.96, a P/E/G ratio of 108.76 and a beta of 0.80.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. Omnicell’s revenue was down 7.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.29 EPS. As a group, equities analysts anticipate that Omnicell will post 0.25 earnings per share for the current year.

Hedge Funds Weigh In On Omnicell

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Panagora Asset Management Inc. purchased a new stake in shares of Omnicell during the fourth quarter worth approximately $1,319,000. Vanguard Group Inc. raised its position in Omnicell by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after acquiring an additional 80,312 shares in the last quarter. Mutual of America Capital Management LLC raised its position in Omnicell by 197.9% in the first quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock worth $3,642,000 after acquiring an additional 82,774 shares in the last quarter. SG Americas Securities LLC purchased a new position in Omnicell in the first quarter worth $684,000. Finally, Cadian Capital Management LP purchased a new position in Omnicell in the fourth quarter worth $2,446,000. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.